Combining entinostat with anti-PD-1 or anti-CTLA-4 significantly decreased the suppression by PMN-MDSCs, increased in activated granzyme-B producing CD8+ T cells, and improved the tumor-free survival in both breast cancer and pancreatic cancer [146]. Here, CTLA4 is linked to neoplasm.